ProQR Therapeutics (PRQR)
(Delayed Data from NSDQ)
$2.12 USD
+0.05 (2.17%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $2.12 +0.01 (0.24%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PRQR 2.12 +0.05(2.17%)
Will PRQR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PRQR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRQR
Techne (TECH) Q3 Earnings and Revenues Beat Estimates
Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength?
PRQR: What are Zacks experts saying now?
Zacks Private Portfolio Services
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
Krystal Biotech, Inc. (KRYS) Beats Q3 Earnings and Revenue Estimates
Best Momentum Stocks to Buy for October 2nd
Other News for PRQR
ProQR Announces Upcoming Presentation at RNA Editing Summit | PRQR Stock News
ProQR Therapeutics (PRQR) Target Price Boosted by Evercore ISI | PRQR Stock News
ProQR Therapeutics price target raised by $1 at Evercore ISI, here's why
PRQR: Cantor Fitzgerald Reiterates Overweight Rating | PRQR Stock News
ProQR Therapeutics (PRQR) Analyst Rating Maintained by JMP Securities | PRQR Stock News